ABSTRACT
OBJECTIVE: To elucidate the clinical importance of the anti-signal recognition particle (SRP) autoantibody in patients with myositis. METHODS: Retrospective systematic assessment of the clinical, laboratory and histological characteristics of 23 anti-SRP-positive patients from six European centres. Data were compared with a large group of anti-SRP-negative patients with myositis published previously. RESULTS: Clinically, patients with anti-SRP autoantibodies often had a severe symmetric proximal muscle weakness resulting in marked disability, dysphagia and highly elevated levels of serum creatine kinase. Three patients had typical dermatomyositis rashes. The disease was associated with the occurrence of extramuscular signs and symptoms including interstitial lung disease. No association was found with an increased risk of cardiac involvement, and the disease carried a reasonably favourable prognosis with most patients responding to treatment. None of the patients had the typical histological features of myositis. Most muscle biopsy specimens showed the presence of necrotic muscle fibres and no inflammatory infiltrates. CONCLUSIONS: Anti-SRP autoantibodies are associated with a syndrome of a necrotising myopathy in the spectrum of immune-mediated myopathies that differs from typical polymyositis. Further studies are needed to elucidate the pathogenesis and to clarify the role of the anti-SRP autoantibodies in this unique disease.
Subject(s)
Autoantibodies/blood , Autoimmune Diseases/immunology , Polymyositis/immunology , Signal Recognition Particle/immunology , Adult , Autoimmune Diseases/drug therapy , Autoimmune Diseases/pathology , Biomarkers/blood , Biopsy , Creatine Kinase/blood , Dermatomyositis/complications , Dermatomyositis/drug therapy , Dermatomyositis/immunology , Dermatomyositis/pathology , Female , Humans , Immunologic Factors/therapeutic use , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/immunology , Male , Middle Aged , Muscle Weakness/etiology , Muscle Weakness/immunology , Muscular Atrophy/etiology , Muscular Atrophy/immunology , Muscular Atrophy/pathology , Polymyositis/complications , Polymyositis/drug therapy , Polymyositis/pathology , Prognosis , Retrospective Studies , Treatment OutcomeABSTRACT
OBJECTIVES: To assess the clinical implications of autoantibodies directed against different parts of the Mi-2 beta autoantigen in patients with myositis. METHODS: A systematic assessment of the clinical, laboratory, and histological characteristics of 48 anti-Mi-2 positive patients from six European centres was made. Anti-Mi-2 autoantibodies were determined with an ELISA using four overlapping fragments spanning the entire amino acid sequence of the autoantigen. Data were compared with results for a large group of anti-Mi-2 negative patients with myositis published previously. RESULTS: Anti-Mi-2 autoantibodies were found in dermatomyositis, polymyositis, and inclusion body myositis. In general, myositis with anti-Mi-2 autoantibodies was characterised by relatively mild disease, sometimes accompanied by extra-muscular symptoms, including arthralgia, arthritis, Raynaud's phenomenon, and interstitial lung disease. Cardiac disease was not seen, and treatment response was fair. No differences were found between patients with autoantibodies to different fragments of the Mi-2 beta antigen, except for a potentially increased risk of cancer in patients with antibodies directed to the N-terminal fragment of the autoantigen. CONCLUSIONS: Anti-Mi-2 autoantibodies are not a marker of a specific subtype of myositis. No significant differences between patients with autoantibodies to different fragments of the Mi-2 beta autoantigen are found, with the possible exception of an increased risk of cancer in patients with antibodies to the N-terminal fragment.
Subject(s)
Adenosine Triphosphatases/immunology , Autoantibodies/blood , Autoantigens/immunology , DNA Helicases/immunology , Myositis/immunology , Chi-Square Distribution , Enzyme-Linked Immunosorbent Assay , Europe , Female , Humans , Male , Mi-2 Nucleosome Remodeling and Deacetylase Complex , Muscular Atrophy/complications , Muscular Atrophy/immunology , Myositis/complications , Neoplasms/etiology , Peptide Fragments/immunology , Raynaud Disease/complications , Raynaud Disease/immunology , Risk Assessment , Statistics, NonparametricABSTRACT
Myositis specific autoantibodies (MSAs) are proven to be specific for myositis compared with other inflammatory connective tissue diseases. Their specificity compared, however, with other neuromuscular disorders, which are included in the differential diagnosis of patients in whom the diagnosis myositis is under consideration, is unknown. We prospectively screened sera from 107 patients with various neuromuscular disorders for the most common MSAs and compared the results with the findings in a group of 97 myositis patients, published previously. Special attention was paid to patients with facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant muscle disease with marked inflammation in skeletal muscle tissue. Only one patient in the neuromuscular disorders group tested positive for an MSA, compared with 41 in the myositis group, resulting in a specificity of 99%. None of the FSHD patients tested positive. We conclude that the tested MSAs are highly specific for myositis and that they are not merely associated with muscle inflammation.
